Adgero

Adgero

Adgero

Adgero Biopharmaceuticals is leveraging its late stage photodynamic therapy (PDT) platform for the treatment of serious oncology indications.
Founded
2012
Raised
$2M
Follow us
Alexa global traffic share
Twitter followers
Latest funding
$2,000,000
Venture capital - 2017
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical
Team Size
2
Employees
$2,000,000 Venture capital
Marketwire

Adgero Biopharmaceuticals Holdings Inc. Announces $2.0 Million Investment from Strategic Asian Investor

$9,700,000 Venture capital
Marketwire

Adgero Biopharmaceuticals Completes $9.7 Million Equity Financing

Health
Ecosummit

Adgero Market

Self driving cars Energy